Large Israeli Study Finds Modern Hormone Therapy Not Tied to Heart Disease Risk

A 12-year study of over 52,000 women in Israel found that contemporary hormone replacement therapy did not increase the risk of heart attack, stroke, blood clots or early death, potentially easing long-standing safety concerns.

Houston Metrowire Staff
••Healthcare
Large Israeli Study Finds Modern Hormone Therapy Not Tied to Heart Disease Risk

A large, long-term study of more than 52,000 women in Israel found that initiating contemporary hormone replacement therapy (HRT) between ages 45 and 59 was not associated with an increased risk of heart attack, stroke, blood clots or death, according to preliminary research to be presented at the American Heart Association's Scientific Sessions 2026.

The findings matter because fear of heart-related harm is one of the most common reasons women decline hormone therapy for menopause symptoms, and why some clinicians hesitate to prescribe it. "Concerns that hormone replacement therapy may affect the heart is one of the most common reasons women decline hormone therapy to manage menopause symptoms, and why some healthcare professionals may hesitate to offer it," said lead researcher Ronen Arbel, Ph.D., of Clalit Health Services in Tel Aviv and Sapir College's Maximizing Health Outcomes Research Lab.

Earlier randomized trials produced mixed results and relied heavily on older HRT formulations at higher doses, often started years after menopause. Current guidelines from the American College of Obstetricians and Gynecologists recommend starting HRT within 10 years of menopause onset and before age 60. In November 2025, the FDA removed the "black box" warnings from HRT products after reviewing data indicating no increased risk of cardiovascular disease, breast cancer or dementia.

The study evaluated records for 52,330 women aged 45 to 59 with no history of heart disease, blood clots or cancer. Half had started HRT, mainly oral or transdermal, while the other half had recently seen a gynecologist but did not begin therapy. Researchers matched the groups by age, BMI, cardiometabolic risk factors, smoking and socioeconomic status, then followed them for up to 23 years, with an average of 12 years. The primary outcomes included atherosclerotic cardiovascular disease, venous thromboembolism and premature death before age 80.

Heart attack, stroke or related heart disease occurred in 4.4% of the HRT group versus 4.6% of the no-HRT group. Death before 80 occurred in 1.3% versus 1.2%, and blood clots in 0.33% of both groups. Results were similar across oral, patch and gel formulations. "Our results indicate that, for women in their mid-forties to late fifties with no history of heart disease or blood clots, the currently available hormone therapies prescribed to manage menopause symptoms do not appear to raise the risk of heart attack, stroke, clots or early death, even after long-term use," Arbel said.

Stacey E. Rosen, M.D., FAHA, past volunteer president of the American Heart Association, said the study "adds to growing evidence that today's hormone therapy options may not increase the risk of heart disease, stroke or blood clots for healthy women who begin treatment around the time of menopause." Rosen, executive director of the Katz Institute for Women's Health at Northwell Health, was not involved in the research.

The authors caution that the observational design cannot prove cause and effect, and that unmeasured differences such as exercise, diet and symptom severity may persist. The abstract is not peer-reviewed and is considered preliminary until published in a peer-reviewed journal. The work will be presented at Scientific Sessions 2026, and additional materials, including a Spanish news release, are available through the release link. A related American Heart Association statement, Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention, provides context on timing and prevention.

Blockchain Registration

QR Code for Blockchain Registration